Safety and Efficacy Comparison of TG-873870(Nemonoxacin) to Levofloxacin in Community-Acquired Pneumonia

Inclusion Criteria:

• If female, non-lactating and at no risk or pregnancy (post-menopausal or must use adequate birth control)
• Must be a suitable candidate for oral antibiotic therapy and must be able to swallow capsules intact
• Must have a clinical diagnosis of CAP based on clinical evidence
• Must have a chest radiograph demonstrating new or persistent/progressive infiltrates
• Must be able to produce sputum

Exclusion Criteria:

• Clinically significant conduction or other abnormality on 12-lead ECG, or QTc interval
• Patients with CAP that, in the investigator's judgment, is severe enough to require hospitalization for intravenous antibiotic therapy and/or supplemental oxygen therapy with ICU support
• Known or suspected severe bronchiectasis, cystic fibrosis, active pulmonary tuberculosis or infection with other mycobacteria or fungi, known bronchial obstruction, a history of post-obstructive pneumonia, other confounding respiratory diseases, such as lung cancer, malignancy metastatic to the lungs, lung abscess, empyema, suspected aspiration pneumonia due to vomiting, or non-bacterial respiratory infection (chronic obstructive pulmonary disease [COPD] is not exclusionary)
• Infection acquired in a hospital, nursing home, or other long-term care facility, or hospitalization for any reason within the previous 14 days
• Treatment with any antibiotics within the past 7 days prior to randomization, unless documents to be a treatment failure(72 hours treatment and not responding)
• Anticipation of the requirement for additional treatment with non-study antibacterials for any reason during the patient's participation in the study
• Treatment with chemotherapeutic agents or oncolytics during the 6 months prior to randomization or anticipated requirement for such agents during the course of the study
• Known or suspected CNS disorder that may predispose the patient to seizures or lower the seizure threshold